PTC Therapeutics begins Phase III trial of Translarna to treat nonsense mutation cystic fibrosis

US-based biopharmaceutical firm PTC Therapeutics has started a global confirmatory Phase III clinical trial of Translarna (ataluren), an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news